Sagent Pharmaceuticals names new business development chief

SCHAUMBURG - Sagent Pharmaceuticals has hired Sean Brynjelsen as executive vice president, business development.

Brynjelsen will develop and execute a strategy to drive long-term growth through the acceleration of product licensing, acquisition of products and portfolios as well as the execution of other M&A activity. He will report to Allan Oberman, Sagent's Chief Executive Officer.

Brynjelsen joins Sagent to lead the third objective of its "Triple E" growth strategy to execute on strategic M&A transactions to advance our growth and profitability, said Oberman.

"Sean has extensive experience in pharmaceutical transactions, strategic planning and product licensing/development, which makes him a great addition to our executive leadership team," he added. "This newly created position, in conjunction with the addition of our EVP of Global Operations earlier this quarter, fulfills our commitment to strengthen the leadership of Sagent and support the acceleration of our ability to execute on our growth strategy."

Brynjelsen has over 20 years of transactional experience in the pharmaceutical industry with companies including Akorn, Hospira and Baxter. Most recently, he served as senior vice president, global business development for Akorn where he completed over 100 transactions including the acquisition of over 25 products contributing greater than $300 million of annual revenue. He earned an MBA from the University of Notre Dame and holds a master of science in chemistry and a bachelor of science in biochemistry from the University of Illinois.